Objective Neurodegenerative disorders such as, Alzheimer’s disease (AD), Mild Cognitive Impairment (MCI), stroke, Traumatic Brain Injury (TBI) and chronic stress create a major economic burden to society and a substantial reduction in quality of life for patients and families. The development of neuroregenerative therapies is notoriously difficult and requires significant investment. NeuroFGL will contribute to decrease these barriers through: (1) the clinical advancement of a promising novel regenerative therapy (FGLs) for neurological disorders, (2) hedging the clinical development by developing tests that enable early clinical assessments to be made, thereby maximising the chance that FGL and other neurogenerative therapies actually become developed to the benefit of patients and society; and (3) Selecting a target patient population with less variability and thereby easier to study – reducing and time resources needed, and increase predictability . FGLs is a promising and novel regenerative therapy being the clinical lead development candidate selected from a group of allosteric FGF-receptor modulators (referred to as FGL) mimicking NCAM. FGL has demonstrated positive effects in a number of in vivo models of neurodegeneration, e.g. beta-amyloid induced toxicity, global ischemia and chronic stress. The in vivo effects of FGL suggest a disease-modifying activity in several neurodegenerative disorders, such as neurogenesis. A phase I clinical study has demonstrated a FGL peptide to be well tolerated and safe. NeuroFGL will refine existing and develop new tests and techniques, that will at an early stage of the clinical development: (1) provide better information on the mechanisms of action (NCAM mimicking allosteric FGF recoter modulation) in man, (2) deliver translational effects seen between animal and man, (3) provide results earlier and cheaper, increasing the iteratiation and (4) select patients with conditions associated with less variability, e.g. patients with AD with a specific EEG or patients progressing to AD identified in patients with MCI. These developments will together provide a more robust basis for the development of FGLs, other drugs with a similar mechanism of action and other therapies for neurodegenerative disorders. Fields of science natural sciencesbiological sciencesneurobiologymedical and health sciencesbasic medicineneurologydementiaalzheimernatural sciencesbiological sciencesbiochemistrybiomoleculesmedical and health sciencesbasic medicineneurologystroke Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Topic(s) HEALTH.2011.1.4-1 - Regenerative medicine clinical trials Call for proposal FP7-HEALTH-2011-two-stage See other projects for this call Funding Scheme CP-FP - Small or medium-scale focused research project Coordinator KOBENHAVNS UNIVERSITET EU contribution € 240 806,15 Address NORREGADE 10 1165 Kobenhavn Denmark See on map Region Danmark Hovedstaden Byen København Activity type Higher or Secondary Education Establishments Administrative Contact Ivan Kristoffersen (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Participants (6) Sort alphabetically Sort by EU Contribution Expand all Collapse all ENKAM PHARMACEUTICALS A/S Denmark EU contribution € 3 985 513,85 Address Fruebjergvej, 3 2100 COPENHAGEN See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Morten Albrechtsen (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data FORENAP PHARMA Participation ended France EU contribution No data Address RUE DU 4EME SPAHIS MAROCAINS 27 68250 ROUFFACH See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Sandra Werner (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data H. LUNDBECK AS Denmark EU contribution € 39 999,00 Address OTTILIAVEJ 7-9 2500 Valby See on map Region Danmark Hovedstaden Byen København Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Jan Egebjerg (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Qualissima France EU contribution € 1 100 500,00 Address Rue Clapier 13001 Marseille See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Severine Pitel (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data KLINIKUM DER UNIVERSITAET ZU KOELN Germany EU contribution € 394 674,00 Address Kerpener Strasse 62 50937 Koeln See on map Region Nordrhein-Westfalen Köln Köln, Kreisfreie Stadt Activity type Higher or Secondary Education Establishments Administrative Contact Jutta Landvogt (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data NARODNI USTAV DUSEVNIHO ZDRAVI Czechia EU contribution € 217 242,00 Address TOPOLOVA 748 250 67 Klecany See on map Region Česko Střední Čechy Středočeský kraj Activity type Research Organisations Administrative Contact Alexandr Borovicka (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data
